Abstract: Described herein are materials and methods for stratifying risk for reactivation of a latent viral infection, such as CMV infection. The methods are particularly useful for immune compromised subjects. Also described herein are interventions, including therapeutic, prophylactic, and monitoring interventions, for subjects determined to be at elevated risk.

Abstract: A pharmaceutical composition for use in preventing or treating graft versus host disease (GVHD) in a subject wherein the composition includes intact microvesicles isolated from a biological fluid using polyethylene glycol (PEG) precipitation, wherein administration of the pharmaceutical composition alleviates or prevents one or more symptoms of GVHD in the subject. Also described is a method of preventing or treating graft versus host disease (GVHD) in a subject comprising administering to the subject a pharmaceutical composition comprising intact microvesicles isolated from a biological fluid of an unrelated or related donor using polyethylene glycol (PEG) precipitation wherein one or more symptoms of GVHD comprising weight loss, cutaneous tissue damage, subcutaneous tissue damage, cutaneous inflammation, satellite cell necrosis, truncated lifespan, and/or subcutaneous inflammation are prevented or alleviated in the subject.

Abstract: The present invention relates to methods for modulating regulatory T cells (Tregs) for use, e.g., in treating or preventing graft-versus-host disease (GVHD) in a transplant recipient.

Abstract: Described herein are materials and methods for stratifying risk for reactivation of a latent viral infection, such as CMV infection. The methods are particularly useful for immune compromised subjects. Also described herein are interventions, including therapeutic, prophylactic, and monitoring interventions, for subjects determined to be at elevated risk.

Abstract: Alloreactive immune cell populations, clinical uses thereof and a means for specifically depleting alloreactive immune cells, while sparing other immune cell populations and thereby retaining broad specificity for other immune stimuli are disclosed. The present disclosure relates a means for specifically depleting alloreactive T cells, while sparing other T cell populations with a sorting strategy utilizing phenotypic characteristics to specifically deplete alloreactive T cells while retaining broad specificity for other stimuli, including viral antigens and third party alloantigens, specifically depleted alloreactive T cell populations and clinical uses of such specifically depleted alloreactive T cell populations.